<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709796</url>
  </required_header>
  <id_info>
    <org_study_id>BC-08429</org_study_id>
    <nct_id>NCT04709796</nct_id>
  </id_info>
  <brief_title>The Use of High Concentration Hyaluronic Acid (HA) Transfer Medium in Repeated Implantation Failure (RIF) Patients</brief_title>
  <acronym>RIFLE</acronym>
  <official_title>The Use of High Concentration Hyaluronic Acid (HA) Transfer Medium in Repeated Implantation Failure (RIF) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study with the aim to investigate the beneficial effect of bicarbonate&#xD;
      buffered medium containing hyaluronan and recombinant human albumin (EmbryoGlue®, Vitrolife)&#xD;
      in patients with documented repeated implantation failure on live birth per randomized&#xD;
      subject as primary endpoint.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth</measure>
    <time_frame>9 months after embryo transfer</time_frame>
    <description>live birth per randomized subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>positive hCG</measure>
    <time_frame>11 days (± 2 days) after embryo transfer.</time_frame>
    <description>cumulative positive hCG rate confirmed by blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>between 6 and 8 weeks of gestation</time_frame>
    <description>cumulative ongoing pregnancy rate per randomized subject, confirmed by ultrasound</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>IVF</condition>
  <condition>Embryo Loss</condition>
  <condition>Miscarriage, Recurrent</condition>
  <arm_group>
    <arm_group_label>Intervention group: EmbryoGlue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Embryo transfer with EmbryoGlue®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional embryo transfer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EmbryoGlue®, Vitrolife</intervention_name>
    <description>The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent.</description>
    <arm_group_label>Intervention group: EmbryoGlue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional Transfer</intervention_name>
    <description>The control arm is the conventional embryo transfer without Embryo glue medium</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The trial only includes women with a clinical indication for ART with a history of RIF&#xD;
             defined as the absence of implantation after two consecutive cycles of IVF, ICSI or&#xD;
             frozen embryo replacement cycles where the cumulative number of transferred embryos&#xD;
             was no less than four for cleavage-stage embryos and no less than two for blastocysts,&#xD;
             with all embryos being of good quality and of appropriate developmental stage.&#xD;
&#xD;
        Furthermore, other specific 'RIF' investigations were performed and treated if necessary:&#xD;
&#xD;
          -  Normal hysteroscopy&#xD;
&#xD;
          -  Normal karyotype of both parents&#xD;
&#xD;
          -  Coagulation screening (Antitrombine II deficiency, Factor VIII augmentation, APC&#xD;
             resistance, Factor V + Factor II augmentation, Protein S and C deficiency an&#xD;
             homocysteine augmentation)&#xD;
&#xD;
          -  Auto-immune screening (Lupus anticoagulant, Rheumatoid Factor, Anti-nuclear&#xD;
             antibodies, Anti-cardiolipine antibodies and Glycoprotein-1-antibodies)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Simultaneous participation in another clinical study&#xD;
&#xD;
               -  Untreated and uncontrolled thyroid dysfunction&#xD;
&#xD;
               -  Tumors of the ovary, breast, uterus, pituitary or hypothalamus&#xD;
&#xD;
               -  Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause&#xD;
&#xD;
               -  Ovarian cysts or enlarged ovaries&#xD;
&#xD;
               -  Malformations of the reproductive organs&#xD;
&#xD;
               -  Moderate or severe hepatic impairment&#xD;
&#xD;
               -  Current use of oral contraceptives, anti-psychotics, anti-epileptics or&#xD;
                  chemotherapy&#xD;
&#xD;
               -  Patients who undergo preimplantation genetic testing (PGT), fertility&#xD;
                  preservation or oocyte donation&#xD;
&#xD;
               -  Couples needing TESE/MESA material&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominic Stoop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Stoop</last_name>
      <phone>09/332.16.99</phone>
      <email>dominic.stoop@uzgent.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
    <mesh_term>Embryo Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

